A‐1 treatment reduced motor neuron loss, improved gastrocnemius atrophy, and delayed ALS progression through the AMPK/SIRT1/PGC‐1α pathway, which promotes mitochondrial biogenesis. Here, SIRT1 is linked to amyotrophic lateral sclerosis.